Oppenheimer raised the firm’s price target on Trevi Therapeutics (TRVI) to $12 from $9 and keeps an Outperform rating on the shares. The firm remains a buyer into the upcoming RIVER data in RCC.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI: